Literature DB >> 6202514

Selective amplification in methotrexate-resistant mouse cells of an artificial dihydrofolate reductase transcription unit making use of cryptic splicing and polyadenylation sites.

R Breathnach.   

Abstract

We have constructed a recombinant ( pMOP ) which is based on the bacterial plasmid pML2 and contains bovine papilloma virus type 1 (BPV 1) sequences linked to an artificial mouse dihydrofolate reductase (DHFR) transcription unit. This unit consists of the SV40 early gene promoter, a complete DHFR coding sequence and splice and polyadenylation sites from a rabbit beta-globin gene. Intact pMOP or a fragment thereof devoid of pML2 sequences will transform mouse cells to methotrexate resistance. The lines obtained contain approximately 200 copies of the DHFR transcription unit. In no case, however, did we find evidence of extrachromosomal maintenance of BPV 1 or DHFR sequences. One line, when selected for resistance to elevated levels of methotrexate, contained amplified copies of a 'novel' DHFR transcription unit resulting from fusion of two normal units. This line contained the DHFR RNA species present in the parent line plus some additional species. The structure of these various RNA species was determined and evidence found for the use of cryptic splice and polyadenylation sites.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6202514      PMCID: PMC557445          DOI: 10.1002/j.1460-2075.1984.tb01903.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  25 in total

1.  Biochemical transfer of single-copy eucaryotic genes using total cellular DNA as donor.

Authors:  M Wigler; A Pellicer; S Silverstein; R Axel
Journal:  Cell       Date:  1978-07       Impact factor: 41.582

2.  Phenotypic expression in E. coli of a DNA sequence coding for mouse dihydrofolate reductase.

Authors:  A C Chang; J H Nunberg; R J Kaufman; H A Erlich; R T Schimke; S N Cohen
Journal:  Nature       Date:  1978-10-19       Impact factor: 49.962

3.  Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase.

Authors:  K O'Hare; C Benoist; R Breathnach
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

4.  In vitro tumorigenic transformation by a defined sub-genomic fragment of bovine papilloma virus DNA.

Authors:  D R Lowy; I Dvoretzky; R Shober; M F Law; L Engel; P M Howley
Journal:  Nature       Date:  1980-09-04       Impact factor: 49.962

5.  Genetic and physical linkage of exogenous sequences in transformed cells.

Authors:  M Perucho; D Hanahan; M Wigler
Journal:  Cell       Date:  1980-11       Impact factor: 41.582

6.  Plasmid screening at high colony density.

Authors:  D Hanahan; M Meselson
Journal:  Gene       Date:  1980-06       Impact factor: 3.688

7.  Comparison of total sequence of a cloned rabbit beta-globin gene and its flanking regions with a homologous mouse sequence.

Authors:  A van Ooyen; J van den Berg; N Mantei; C Weissmann
Journal:  Science       Date:  1979-10-19       Impact factor: 47.728

8.  Equine connective tissue tumors contain unintegrated bovine papilloma virus DNA.

Authors:  E Amtmann; H Müller; G Sauer
Journal:  J Virol       Date:  1980-09       Impact factor: 5.103

9.  Corrected splicing of a chicken ovalbumin gene transcript in mouse L cells.

Authors:  R Breathnach; N Mantei; P Chambon
Journal:  Proc Natl Acad Sci U S A       Date:  1980-02       Impact factor: 11.205

10.  A bovine papilloma virus vector with a dominant resistance marker replicates extrachromosomally in mouse and E. coli cells.

Authors:  P D Matthias; H U Bernard; A Scott; G Brady; T Hashimoto-Gotoh; G Schütz
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

View more
  1 in total

1.  Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences.

Authors:  S Carswell; J C Alwine
Journal:  Mol Cell Biol       Date:  1989-10       Impact factor: 4.272

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.